AstraZeneca PLC (LSE/STO/NASDAQ:LON:AZN), the global biopharmaceutical company, announced today that as of June 30, 2024, its issued share capital consists of 1,550,268,075 ordinary shares with voting rights. The company confirmed that no shares are currently held in Treasury, which means the total number of voting rights in the company stands at 1,550,268,075.
This figure is disclosed in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1 and will be used by shareholders to determine if they are required to notify their interest in AstraZeneca (NASDAQ:AZN) PLC, or a change to their interest, under the Disclosure and Transparency Rules.
Headquartered in Cambridge, UK, AstraZeneca is focused on the discovery, development, and commercialization of prescription medicines, particularly in the areas of Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. The company's products are available in over 125 countries and are used by millions of patients worldwide.
The information provided in this announcement is based on a press release statement from the company. AstraZeneca has a strong presence in the pharmaceutical industry, with a commitment to advancing medical science and improving the health outcomes of patients globally.
Investors and shareholders may consider this update on voting rights as part of their ongoing assessment of the company's performance and governance. AstraZeneca's dedication to transparency and adherence to regulatory requirements reflects its ongoing commitment to good corporate practices.
In other recent news, AstraZeneca's drugs Lynparza and Imfinzi have received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use for treating advanced or recurrent endometrial cancers, based on the DUO-E Phase III clinical trial results.
In parallel, AstraZeneca's Imfinzi, in combination with chemotherapy, has shown a statistically significant improvement in event-free survival and overall survival for patients with muscle-invasive bladder cancer, according to results from the NIAGARA Phase III trial. Still, Imfinzi did not meet the primary endpoint of disease-free survival in the ADJUVANT BR.31 Phase III trial for early-stage non-small cell lung cancer.
On a positive note, the U.S. Food and Drug Administration has approved AstraZeneca's Imfinzi for treating adults with primary advanced or recurrent endometrial cancer that is mismatch repair deficient.
These developments have led analyst firms Citi, BMO Capital, and Deutsche Bank to maintain positive ratings on AstraZeneca's shares. AstraZeneca's CEO, Pascal Soriot, also recently transferred a significant number of shares to family members. It's important to note that these are recent developments and are subject to change.
InvestingPro Insights
As AstraZeneca PLC (NASDAQ:AZN) continues to maintain its robust presence in the pharmaceutical industry, recent data from InvestingPro indicates a promising financial outlook for the company. With a market capitalization of $243.34 billion and a revenue growth of 8.6% over the last twelve months as of Q1 2024, AstraZeneca stands out for its financial strength. The company also boasts a high gross profit margin of 82.5%, underscoring its efficiency in maintaining profitability.
Two InvestingPro Tips that investors should consider are that AstraZeneca's net income is expected to grow this year, and two analysts have revised their earnings upwards for the upcoming period. These insights suggest a positive trajectory for the company's financial performance, which could influence investment decisions.
Moreover, AstraZeneca has a history of reliability for income-focused investors, having maintained dividend payments for 32 consecutive years, with a dividend yield of 2.47% as of the last recorded date.
For those interested in deeper analysis and additional insights, InvestingPro offers more tips on AstraZeneca, including the company's trading patterns and debt management. Unlock these valuable insights and enhance your investment strategy with InvestingPro. Use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription. With numerous additional tips available, investors can make more informed decisions based on comprehensive data and expert analysis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.